NEW YORK, May 18, 2017 (GLOBE NEWSWIRE) -- argenx (Nasdaq:ARGX), a clinical-stage biotechnology company developing a deep
pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, visited the Nasdaq
MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/5b098cb8-6dcf-4f30-b37d-2d4a7b0176a9
“We are delighted to have completed our successful US IPO which will support the growth of our business, particularly as we
advance our lead clinical programs ARGX-113 for severe autoimmune disease and ARGX-110 for hematological malignancies through key
phase 2 trials and forward,” said Tim Van Hauwermeiren, CEO of argenx. “Establishing US trading for our stock is another element in
our strategy to access the world’s most significant pharmaceutical market and other important stakeholders as we work to bring our
novel products to the patients who need them.”
Based in Breda, the Netherlands, argenx is focused on developing product candidates with the potential to be either
first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a
significant unmet medical need. Together with its antibody discovery and development expertise, argenx employs a suite of
technologies to optimize antibodies for the discovery and development of the company’s product candidates.
“As the leading exchange for many successful health care companies, we are proud to be the listing partner of argenx as they
continue to drive forward the development of antibody engineering to treat patients with cancer and severe autoimmune diseases,”
said Nelson Griggs, Executive Vice President, Head of Global Listings, Nasdaq.
The information contained above is provided for informational and educational purposes only, and nothing contained herein
should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information
about the company is provided by the company or comes from the company’s public filings and is not independently verified by
Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation
about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future
performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future
results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A
SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and
public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their
business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first electronic stock market, its technology powers more than 89 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11
trillion. To learn more, visit: http://business.nasdaq.com.
- NDAQG -
Media Relations Contacts: Stephanie Lowenthal (646) 441-5073 Stephanie.Lowenthal@nasdaq.com Emily Pan (646) 441-5120 emily.pan@nasdaq.com